Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine versus aprepitant for prevention of cisplatin-induced nausea and vomiting
ChiCTR-TTRCC-14004093Phase 3Completed
- Sponsor
- The Second Xiangya Hospital
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine and aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Vomiting. Started Apr 2014; status: completed.
02
Drugs
olanzapineaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR-TTRCC-14004093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TTRCC-14004093.